SIU 2017: Demystifying the Mechanistic and Functional Aspects of RNA Activation With Double-Stranded RNAs in Human Prostate Cancer Cells
Lisbon, Portugal (UroToday.com) The recently identified phenomenon of double-stranded RNA (dsRNA)-mediated gene activation (RNAa) has been studied extensively. It is present in humans, mice, and Caenorhabditis elegans, suggesting that dsRNA-mediated RNAa is an evolutionarily mechanism.
SIU 2017: Role of Growth Hormone-Releasing Hormone on Prostate Cancer
Lisbon, Portugal (UroToday.com) The involvement of growth hormone-releasing hormone (GHRH) and its receptors in several relevant processes that contribute to prostate cancer progression has been described. However, the role of such a neuropeptide on cell transformation through epithelial-mesenchymal transition (EMT) is still unknown. In this study the authors aimed to compare the expression of GHRH receptors (pCHRH-R) and their splice variants (SVs) as well as to study the carcinogenic potential of GHRH on human prostate cells.
SIU 2017: Lymphovascular Invasion ls a Stage-Specific Risk Factor for Systemic Recurrence after Nephroureterectomy in Patients with Upper Tract Urothelial Carcinoma
Lisbon, Portugal (UroToday.com) The aim of this study was to clarify the oncological outcomes of lymphovascular invasion (LVI) in different clinical stages in patients with upper tract urothelial carcinoma (UTUC) after nephroureterectomy.
SIU 2017: Kidney Resection in Patients with Urothelial Cancer
Lisbon, Portugal (UroToday.com) Partial nephrectomy in patients with urothelial tumors is a rare type of surgery and can be performed only in cases of localized small tumors of the calyx when renal function is preserved. The aim of his study was to evaluate short and long term functional and oncological outcomes of patients who underwent partial nephrectomy due to urothelial carcinoma.
SIU 2017: Efficiency of the Renal Cancer Specialist Multidisciplinary Team Meeting: Results from 1500 discussions
Lisbon, Portugal (UroToday.com) In the UK, all cancer cases must be reviewed at multidisciplinary team (MDT) meetings. The authors report on the efficiency of the renal cancer specialist MDT (sMDT) meetings at their high-volume specialist center.
SIU 2017: Bellini Duct Renal Cell Carcinoma – an Aggressive Tumor that Requires Thorough Monitoring
Lisbon, Portugal (UroToday.com) Bellini duct carcinoma occurs in less than 1% of all malignant kidney tumors and is thought to be very aggressive. The aim of our study was to identify clinical features and treatment options in patients with this rare aggressive tumor.
SIU 2017: Neoadjuvant Targeted Therapy in the Treatment of Localized RCC
Lisbon, Portugal (UroToday.com) Targeted therapy (TT) significantly increases survival of patients with metastatic renal cell cancer (RCC), decreasing the size of the primary tumor as well. The objective of this study was to assess the efficacy of neoadjuvant TT on kidney tumor size with subsequent nephron-sparing surgery in the treatment of localized RCC.